Claritas Genomics, a US-based company developing sequencing tests for genetic paediatric disorders, raised $15m on Monday from a series B round led by life sciences company NextCode Health.
The round also included healthcare IT company Cerner Corporation, Boston Children’s Hospital and Cincinnati Children’s Hospital Medical Center. All three previously invested an undisclosed amount in the company’s series A round in 2013.
Claritas and NextCode Health formed a partnership last month to harness NextCode’s big data analysis technology in order to improve performance of Claritas’ genetic tests.
Spun-out of Boston Children’s Hospital in 2013 with the assistance of life sciences company Life Technologies, Claritas has developed more than 100 specialty genetic tests for researchers and clinical providers, with a focus on paediatric medicine.
The funding will be used to launch a range of next-generation tests, and to expand Claritas’ network of paediatric disease experts and commercial operations.